A5064263453- Helicobacter pylori-related gastroenterology studies
- Gastroesophageal reflux and treatments
- Gastric Cancer Management and Outcomes
- Eosinophilic Esophagitis
- Microscopic Colitis
- Antiplatelet Therapy and Cardiovascular Diseases
- Gastrointestinal motility and disorders
- Veterinary medicine and infectious diseases
- Microbial Metabolites in Food Biotechnology
- Mycobacterium research and diagnosis
- Clostridium difficile and Clostridium perfringens research
- Inflammatory Bowel Disease
- Dysphagia Assessment and Management
- Inflammatory mediators and NSAID effects
- PARP inhibition in cancer therapy
- Esophageal Cancer Research and Treatment
- Pharmaceutical studies and practices
- Atrial Fibrillation Management and Outcomes
- Ion Transport and Channel Regulation
- Cancer Cells and Metastasis
- Celiac Disease Research and Management
- Venous Thromboembolism Diagnosis and Management
- Potassium and Related Disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
Seirei Hamamatsu General Hospital
2022
Hamamatsu University School of Medicine
2014-2021
Health First
2015
Summary Background Acid inhibitory effects of proton pump inhibitors ( PPI s) are influenced by CYP 2C19 genotype. In contrast, the potent acid inhibition vonoprazan is not Aim To compare and esomeprazole in relation to Methods Twenty‐eight healthy Japanese volunteers [7 poor metabolisers PM s), 11 intermediate IM 10 rapid RM s)] received four different regimens a randomised crossover manner: (i) 20 mg twice daily (b.d.), (ii) daily, (iii) b.d. (iv) daily. The timing each dosing was 1 h...
Backgrounds/Aims: Vonoprazan (VPZ) is the first clinically available potassium competitive acid blocker. This class of agents provides faster and more potent inhibition than proton pump inhibitors. Most strains Helicobacter pylori are sensitive to amoxicillin. We hypothesized that dual therapy with VPZ amoxicillin would provide sufficient eradication rate for H. infection. To evaluate this, we compared by VPZ/amoxicillin standard triple VPZ/amoxicillin/clarithromycin therapy. Methods:...
Summary Background Vonoprazan (V), a potassium‐competitive acid blocker, has more durable acid‐inhibitory effect as compared with standard‐dose proton pump inhibitors (PPIs) but not been 2‐4 times higher daily PPI doses administered in two divided doses. Aims To evaluate the of V 10/20 mg once‐daily (OD; V10/V20) vs rabeprazole (R) twice‐daily (BID; R20/R40) healthy Japanese volunteers. Methods This multicentre, randomised, open‐label, two‐period, crossover study V10 or V20 R20, R40 using...
Although autoimmune gastritis (AIG) is generally considered relatively rare, we frequently encounter AIG among patients at to our hospital who have experienced least two episodes of Helicobacter pylori eradication failure.We investigated the incidence in consecutive consulted department for H. with reference history.A total 404 visited pylori-specific out-patient unit from June 2015 2017 were enrolled. Of these, 137 treatment-naive, 47 had failed treatment once (single failure), and 220...
Summary Background Bacterial resistance of Helicobacter pylori to antibiotics is increasing and it often leads failure antibiotic treatment. A new sitafloxacin‐based triple therapy was developed counter this situation; the fluoroquinolone sitafloxacin has a low minimum inhibitory concentration for H. . Aim To investigate efficacy in Japanese patients document its relation anti‐microbial susceptibility. Methods We investigated 1‐week sitafloxicin‐based regimen rabeprazole 10 mg four times...
Drug–drug interaction between antiacid and antiplatelet agents has not been fully elucidated. Vonoprazan, a new potassium competitive acid blocker, available in Japan. CYP2C19 CYP3A4 are involved the metabolism of clopidogrel, prasugrel, esomeprazole, vonoprazan. Using P2Y12 assay, we compared effects vonoprazan esomeprazole on functions clopidogrel or prasugrel 31 healthy Japanese volunteers (14 homo‐extensive (homo‐EMs), nine hetero‐extensive (hetero‐EMs), eight poor metabolizers (PMs))....
Abstract Background Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognostic value expression in esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy (dCRT), platinum derivative nedaplatin. Methods Seventy-three ESCC who received dCRT were examined. analyzed pre-dCRT...
Eradication of H. pylori in patients allergic to penicillin should be performed using regimens without derivatives. We treated a total 28 with proton pump inhibitor (PPI), metronidazole (250 mg bid) and sitafloxacin (100 for one two weeks. At four eight weeks after the treatment, underwent [(13)C]-urea breath test. The overall eradication rate was 100.0%. Mild adverse events were observed. Triple therapy PPI, is well tolerated effective penicillin.
Strong reactive oxygen species (ROS) suppression in cancer stem-like cell components various solid tumors is associated with therapeutic resistance. In this study, we investigated the influence of CD44v8-10 expression on overall survival esophageal squamous carcinoma (E-SCC) patients after definitive chemoradiotherapy (dCRT) and radio-sensitivities E-SCC lines treated or without sulfasalazine, a CD44v8-10-xCT-GSH axis inhibitor.Seventy-three who received dCRT were examined retrospectively....
Healing speed of peptic ulcer is affected by a number factors, including Helicobacter pylori (H. pylori) infection and intragastric pH. Acid inhibition exerted proton pump inhibitors differs CYP2C19 genotype. Herein, we investigated whether healing artificial ulcers formed after endoscopic submucosal dissection (ESD) was influenced H. infection, genotype, or other factors.A total 96 pylori-positive patients with gastric tumors scheduled for ESD were randomly assigned to receive eradication...
<b><i>Background:</i></b> When administered at a standard dose, proton pump inhibitors (PPIs) do not always provide sufficient acid inhibition for all subjects, particularly in extensive metabolizers (EMs) of CYP2C19. Whether esomeprazole dose 20 mg four times daily dosing (q.i.d.) can attain throughout 24 h EMs remains unclear. We therefore investigated the efficacy q.i.d. inhibition. <b><i>Methods:</i></b> In randomized cross-over design, 30...
Spinal kyphotic deformity occasionally results in gastroesophageal reflux disease (GERD). The effects of acid on the esophagus patients are unclear, however, and it is unknown whether reflux, endoscopic GERD, reflux-related symptoms improve following surgical spinal correction these patients. Herein, we investigated characteristics GERD improvement correction.In 48 with severe scheduled for correction, conducted esophagogastroduodenoscopy, 24-h pH monitoring three questionnaire surveys,...
Abdominal compartment syndrome (ACS) is associated with mortality in patients critical illness such as severe acute pancreatitis, but it remains unclear whether decompressive laparotomy for ACS can improve the prognosis of patients. A woman her 60s visited our hospital because upper abdominal pain. On basis laboratory data and contrast-enhanced computed tomography findings, gallstone pancreatitis was diagnosed. She underwent endoscopic sphincterotomy removal common bile duct stone. Then, a...
Abstract Background Prostaglandin E-major urinary metabolite (PGE-MUM) may be a novel biomarker for evaluating disease activity in ulcerative colitis (UC). We compared its usefulness to that of the fecal immunochemical occult blood test (FIT). Methods PGE-MUM and FIT measurements were performed 92 samples obtained from 60 patients with UC. Endoscopic was determined by Mayo endoscopic subscore (eMayo) Ulcerative Colitis Index Severity (UCEIS) score. Results levels results showed significant...
The bacterial resistance of Helicobacter pylori to antimicrobial agents such as clarithromycin and metronidazole has been increasing worldwide, leading the failure eradication treatment. Here, we present an regimen consisting four-times-daily dosing (q.i.d.) rabeprazole with potent acid inhibition.To investigate efficacy therapy q.i.d. amoxicillin or sitafloxacin in Japanese infected a metronidazole-resistant strain.We retrospectively investigated regimens for 7 days 111 pooled patients...
Introduction: Vonoprazan is the first clinically available potassium competitive acid blocker (P-CAB). This class of agents provides faster and more potent inhibition than PPIs. Most strains H. pylori are sensitive to amoxicillin. We hypothesized that dual therapy with a P-CAB amoxicillin would provide sufficient eradication rates for infection. To evaluate this, we compared rate vonoprazan/amoxicillin those standard triple vonoprazan/amoxicillin/clarithromycin therapy. Methods: A total 61...